March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
October 2025 in “Archives of Clinical Toxicology” Cetirizine is effective and safe for treating various allergies, with personalized dosing improving its use.
6 citations
,
February 1996 in “Clinical Pharmacology & Therapeutics” Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.
3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
April 2012 in “Informa Healthcare eBooks” Some drugs for inflammation may cause psoriasis-like hair loss.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
44 citations
,
September 2011 in “Journal of Pediatric Gastroenterology and Nutrition” NISCH syndrome is a rare genetic disorder affecting skin and liver, with variable symptoms and limited treatment options.
Belimumab may cause hair loss in lupus patients.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
104 citations
,
August 2008 in “Clinics in Dermatology” Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.
9 citations
,
October 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Microglia are essential for zebrafish brain repair by controlling inflammation.
2 citations
,
July 2018 in “Our Dermatology Online” Calcipotriol cream reduced skin thickening and itching in a rare nipple condition.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
August 2023 in “Journal of Cosmetic Dermatology” QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.
2 citations
,
February 2018 in “InTech eBooks” TNF-alpha inhibitors can cause various immune-related skin issues.
9 citations
,
July 2018 in “European Journal of Dermatology” Brodalumab effectively treated a man's severe hand and foot psoriasis.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
September 2025 in “Journal of Psychiatry Spectrum” Mirtazapine can cause male breast enlargement.
July 1988 in “Journal of The American Academy of Dermatology” Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
3 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.